NCT06126653 - A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

January 13, 2025

Study Completion Date

January 13, 2025

Conditions

Autism Spectrum Disorder

Interventions

DRUG

Low Dose ARD-501

Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.

DRUG

High Dose ARD-501

Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.

DRUG

Placebo

Titratable, liquid formulation, taken orally.

Trial Locations (1)

Center for Psychiatry and Behavioral Medicine Inc, Las Vegas